



## Vericel to Present at 29th Annual Piper Jaffray Healthcare Conference

November 16, 2017

CAMBRIDGE, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 29th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City, NY on Wednesday, November 29, 2017, at 2:00pm Eastern time.

The presentation will be webcast live at [https://pgi.webcasts.com/viewer/event.jsp?ei=1172021&tp\\_key=ab3cbde8f8](https://pgi.webcasts.com/viewer/event.jsp?ei=1172021&tp_key=ab3cbde8f8), and may be accessed from the news and events section of the Vericel website.

### About Vericel Corporation

Vericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at [www.vcel.com](http://www.vcel.com).

Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.

### Global Media Contacts:

David Schull  
Russo Partners LLC  
+1 212-845-4271 (office)  
+1 858-717-2310 (mobile)  
[David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com)

Karen Chase  
Russo Partners LLC  
+1 646-942-5627 (office)  
+1 917-547-0434 (mobile)  
[Karen.chase@russopartnersllc.com](mailto:Karen.chase@russopartnersllc.com)

### Investor Contacts:

Chad Rubin  
The Trout Group  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)  
+1 (646) 378-2947

Lee Stern  
The Trout Group  
[lstern@troutgroup.com](mailto:lstern@troutgroup.com)  
+1 (646) 378-2922

Source: Vericel Corporation